Tim-3 and Tim-4 as the potential targets for antitumor therapy

Human Vaccines and Immunotherapeutics

Volumn 11, Issue 10, 2015, Pages 2458-2462

  Cheng, Lin ^a   Ruan, Zhihua ^a  

^a THIRD MILITARY MEDICAL UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

CARCINOEMBRYONIC ANTIGEN RELATED CELL ADHESION MOLECULE 1; CD137 ANTIGEN; CD4 ANTIGEN; CYTOTOXIC T LYMPHOCYTE ANTIGEN 4; DNA VACCINE; ECALECTIN; GELATINASE B; HEAT SHOCK PROTEIN 90; HIGH MOBILITY GROUP B1 PROTEIN; INTERLEUKIN 10; INTERLEUKIN 1BETA; INTERLEUKIN 6; INTERLEUKIN 8; KIDNEY INJURY MOLECULE 1; T CELL IMMUNOGLOBULIN AND MUCIN DOMAIN 3; T CELL IMMUNOGLOBULIN AND MUCIN DOMAIN 4; TRANSCRIPTION FACTOR FOXP3; TRANSFORMING GROWTH FACTOR BETA RECEPTOR 1; TUMOR NECROSIS FACTOR; UNCLASSIFIED DRUG; VASCULOTROPIN A; CANCER VACCINE; HAVCR2 PROTEIN, HUMAN; HEPATITIS A VIRUS CELLULAR RECEPTOR 2; MEMBRANE PROTEIN; TIMD4 PROTEIN, HUMAN;

ACUTE MYELOBLASTIC LEUKEMIA; CANCER THERAPY; CYTOTOXIC T LYMPHOCYTE; DENDRITIC CELL; HEMATOPOIESIS; HEMATOPOIETIC STEM CELL; HUMAN; IMMUNE RESPONSE; LIVER CELL CARCINOMA; MELANOMA; NONHUMAN; OVARY CANCER; PROMYELOCYTIC LEUKEMIA; PROTEIN EXPRESSION; REVIEW; SIGNAL TRANSDUCTION; TH1 CELL; TUMOR REJECTION; UPREGULATION; ANIMAL; ANIMAL MODEL; ANTAGONISTS AND INHIBITORS; IMMUNOLOGY; NEOPLASMS; THEORETICAL MODEL;

ANIMALS; CANCER VACCINES; HEPATITIS A VIRUS CELLULAR RECEPTOR 2; HUMANS; MEMBRANE PROTEINS; MODELS, ANIMAL; MODELS, THEORETICAL; NEOPLASMS;

EID: 84951764096     PISSN: 21645515     EISSN: 2164554X     Source Type: Journal    
DOI: 10.1080/21645515.2015.1056953     Document Type: Review

References (45)

1. McIntire JJ, Umetsu SE, Akbari O, Potter M, Kuchroo VK, Barsh GS, Freeman GJ, Umetsu DT, DeKruyff RH. Identification of Tapr (an airway hyperreactivity regulatory locus) and the linked Tim gene family. Nature immunology 2001; 2:1109-16; PMID:11725301; http://dx.doi.org/10.1038/ni739
2. Li Z, Ju Z, Frieri M. The T-cell immunoglobulin and mucin domain (Tim) gene family in asthma, allergy, and autoimmunity. Allergy and asthma proceedings: the official journal of regional and state allergy societies 2013; 34:e21-6; PMID:23406933; http://dx.doi.org/10.2500/aap.2013.34.3646
3. Freeman GJ, Casasnovas JM, Umetsu DT, DeKruyff RH. TIM genes: a family of cell surface phosphatidylserine receptors that regulate innate and adaptive immunity. Immunological reviews 2010; 235:172-89; PMID:20536563
4. Chiba S, Baghdadi M, Akiba H, Yoshiyama H, Kinosh ita I, Dosaka-Akita H, Fujioka Y, Ohba Y, Gorman JV, Colgan JD, et al. Tumor-infiltrating DCs suppress nucleic acid-mediated innate immune responses through interactions between the receptor TIM-3 and the alarmin HMGB1. Nature immunology 2012; 13:832-42; PMID:22842346; http://dx.doi.org/ 10.1038/ni.2376
5. Tang D, Lotze MT. Tumor immunity times out: TIM-3 and HMGB1. Nature immunology 2012; 13:808-10; PMID:22910384; http://dx.doi.org/10.1038/ ni.2396
6. Huang YH, Zhu C, Kondo Y, Anderson AC, Gandhi A, Russell A, Dougan SK, Petersen BS, Melum E, Pertel T, et al. CEACAM1 regulates TIM-3-mediated tolerance and exhaustion. Nature 2015; 517:386-90; PMID:25363763; http://dx.doi.org/10.1038/nature 13848
7. Kobayashi N, Karisola P, Pena-Cruz V, Dorfman DM, Jinushi M, Umetsu SE, Butte MJ, Nagumo H, Chernova I, Zhu B, et al. TIM-1 and TIM-4 glycoproteins bind phosphatidylserine and mediate uptake of apoptotic cells. Immunity 2007; 27:927-40; PMID:18082433; http://dx.doi.org/10.1016/j.immuni.2007.11.011
8. Rodriguez-Manzanet R, Sanjuan MA, Wu HY, Quintana FJ, Xiao S, Anderson AC, Weiner HL, Green DR, Kuchroo VK. T and B cell hyperactivity and autoimmunity associated with niche-specific defects in apoptotic body clearance in TIM-4-deficient mice. Proceedings of the National Academy of Sciences of the United States of America 2010; 107:8706-11; PMID:20368430; http://dx.doi.org/10.1073/pnas.0910359107
9. Miyanishi M, Tada K, Koike M, Uchiyama Y, Kitamura T, Nagata S. Identification of Tim4 as a phosphatidylserine receptor. Nature 2007; 450:435-9; PMID:17960135; http://dx.doi.org/10.1038/ nature06307 www.tandfonline.com
10. Anderson AC. Tim-3, a negative regulator of antitumor immunity. Current opinion in immunology 2012; 24:213-6; PMID:22226204; http://dx.doi.org/10.1016/j.coi.2011.12.005
11. Kikushige Y, Shima T, Takayanagi S, Urata S, Miyamoto T, Iwasaki H, Takenaka K, Teshima T, Tanaka T, Inagaki Y, et al. TIM-3 is a promising target to selectively kill acute myeloid leukemia stem cells. Cell stem cell 2010; 7:708-17; PMID:21112565; http://dx.doi.org/10.1016/j.stem.2010.11.014
12. Kikushige Y, Akashi K. TIM-3 as a therapeutic target for malignant stem cells in acute myelogenous leukemia. Annals of the New York Academy of Sciences 2012; 1266:118-23; PMID:22901263; http://dx.doi. org/10.1111/j.1749-6632.2012.06550.x
13. Kikushige Y, Miyamoto T. TIM-3 as a novel therapeutic target for eradicating acute myelogenous leukemia stem cells. International journal of hematology 2013; 98:627-33; PMID:24046178; http://dx.doi.org/10.1007/s12185-013-1433-6
14. Baghdadi M, Yoneda A, Yamashina T, Nagao H, Komohara Y, Nagai S, Akiba H, Foretz M, Yoshiyama H, Kinoshita I, et al. TIM-4 glycoprotein-mediated degradation of dying tumor cells by autophagy leads to reduced antigen presentation and increased immune tolerance. Immunity 2013; 39:1070-81; PMID:24315994; http://dx.doi.org/10.1016/j.immuni.2013.09.014
15. Ramello MC, Boari JT, Canale FP, Mena HA, Negrotto S, Gastman B, Gruppi A, Rodriguez EV, Montes CL. Tumor-induced senescent T cells promote the secretion of pro-inflammatory cytokines and angiogenic factors by human monocytes/macrophages through a mechanism that involves Tim-3 and CD40L. Cell death & disease 2014; 5:e1507; PMID:25375372; http://dx.doi.org/ 10.1038/cddis.2014.451
16. Fourcade J, Sun Z, Benallaoua M, Guillaume P, Luescher IF, Sander C, Kirkwood JM, Kuchroo V, Zarour HM. Upregulation of Tim-3 and PD-1 expression is associated with tumor antigen-specific CD8C T cell dysfunction in melanoma patients. The Journal of experimental medicine 2010; 207:2175-86; PMID:20819923; http://dx.doi.org/10.1084/jem.20100637
17. Arai Y, Saito H, Ikeguchi M. Upregulation of TIM-3 and PD-1 on CD4C and CD8C T Cells Associated with Dysfunction of Cell-Mediated Immunity after Colorectal Cancer Operation. Yonago acta medica 2012; 55:9; PMID:24031134
18. Sakuishi K, Apetoh L, Sullivan JM, Blazar BR, Kuchroo VK, Anderson AC. Targeting Tim-3 and PD-1 pathways to reverse T cell exhaustion and restore anti- tumor immunity. The Journal of experimental medi- cine 2010; 207:2187-94; PMID:20819927; http://dx.doi.org/10.1084/jem.20100643
19. Fourcade J, Sun Z, Pagliano O, Chauvin JM, Sander C, Janjic B, Tarhini AA, Tawbi HA, Kirkwood JM, Human Vaccines & Immunotherapeutics Moschos S, et al. PD-1 and Tim-3 regulate the expansion of tumor antigen-specific CD8(C) T cells induced by melanoma vaccines. Cancer research 2014; 74:1045-55; PMID:24343228; http://dx.doi.org/10.1158/0008-5472.CAN-13-2908
20. Guo Z, Cheng D, Xia Z, Luan M, Wu L, Wang G, Zhang S. Combined TIM-3 blockade and CD137 activation affords the long-term protection in a murine model of ovarian cancer. Journal of translational medicine 2013; 11:215; PMID:24044888; http://dx.doi.org/10.1186/1479-5876-11-215
21. Pardoll DM. The blockade of immune checkpoints in cancer immunotherapy. Nature reviews Cancer 2012; 12:252-64; PMID:22437870; http://dx.doi.org/10.1038/nrc3239
22. Woo SR, Turnis ME, Goldberg MV, Bankoti J, Selby M, Nirschl CJ, Bettini ML, Gravano DM, Vogel P, Liu CL, et al. Immune inhibitory molecules LAG-3 and PD-1 synergistically regulate T-cell function to promote tumoral immune escape. Cancer research 2012; 72:917-27; PMID:22186141; http://dx.doi.org/10.1158/0008-5472.CAN-11-1620
23. Fourcade J, Sun Z, Pagliano O, Guillaume P, Luescher IF, Sander C, Kirkwood JM, Olive D, Kuchroo V, Zarour HM. CD8(C) T cells specific for tumor antigens can be rendered dysfunctional by the tumor microenvi- ronment through upregulation of the inhibitory receptors BTLA and PD-1. Cancer research 2012; 72:887-96; PMID:22205715; http://dx.doi.org/10.1158/ 0008-5472.CAN-11-2637
24. Yan W, Liu X, Ma H, Zhang H, Song X, Gao L, Liang X, Ma C. Tim-3 fosters HCC development by enhance ing TGF-beta-mediated alternative activation of macrophages. Gut 2015
25. Flecken T, Sarobe P. Tim-3 expression in tumour-associated macrophages: a new player in HCC progression. Gut 2015; PMID:25694141
26. Janku F, McConkey DJ, Hong DS, Kurzrock R. Autophagy as a target for anticancer therapy. Nature reviews Clinical oncology 2011; 8:528-39; PMID:21587219; http://dx.doi.org/10.1038/nrclinonc.2011.71
27. Qadir MA, Kwok B, Dragowska WH, To KH, Le D, Bally MB, Gorski SM. Macroautophagy inhibition sensitizes tamoxifen-resistant breast cancer cells and enhances mitochondrial depolarization. Breast cancer research and treatment 2008; 112:389-403; PMID:18172760; http://dx.doi.org/10.1007/s10549-007-9873-4
28. Carew JS, Medina EC, Esquivel JA, 2nd, Mahalingam D, Swords R, Kelly K, Zhang H, Huang P, Mita AC, Mita MM, et al. Autophagy inhibition enhances vorinostat-induced apoptosis via ubiquitinated protein accumulation. Journal of cellular and molecular medicine 2010; 14:2448-59; PMID:19583815; http://dx.doi.org/10.1111/j.1582-4934.2009.00832.x
29. Apel A, Herr I, Schwarz H, Rodemann HP, Mayer A.Blocked autophagy sensitizes resistant carcinoma cells 2461 to radiation therapy. Cancer research 2008; 68:1485-94; PMID:18316613; http://dx.doi.org/10.1158/0008-5472.CAN-07-0562
30. Baghdadi M, Nagao H, Yoshiyama H, Akiba H, Yagita H, Dosaka-Akita H, Jinushi M. Combined blockade of TIM-3 and TIM-4 augments cancer vaccine efficacy against established melanomas. Cancer immunology, immunotherapy: CII 2013; 62:629-37; PMID:23143694; http://dx.doi.org/10.1007/s00262-012-1371-9
31. Gleason MK, Lenvik TR, McCullar V, Felices M, O’Brien MS, Cooley SA, Verneris MR, Cichocki F, Holman CJ, Panoskaltsis-Mortari A, et al. Tim-3 is an inducible human natural killer cell receptor that enhan- ces interferon gamma production in response to galectin-9. Blood 2012; 119:3064-72; PMID:22323453; http://dx.doi.org/10.1182/blood-2011-06-360321
32. Ndhlovu LC, Lopez-Verges S, Barbour JD, Jones RB, Jha AR, Long BR, Schoeffler EC, Fujita T, Nixon DF, Lanier LL. Tim-3 marks human natural killer cell maturation and suppresses cell-mediated cytotoxicity. Blood 2012; 119:3734-43; PMID:22383801; http://dx.doi.org/10.1182/blood-2011-11-392951
33. da Silva IP, Gallois A, Jimenez-Baranda S, Khan S, Anderson AC, Kuchroo VK, Osman I, Bhardwaj N. Reversal of NK-cell exhaustion in advanced melanoma by Tim-3 blockade. Cancer immunology research 2014; 2:410-22; PMID:24795354; http://dx.doi.org/10.1158/2326-6066.CIR-13-0171
34. Jajosky AN, Coad JE, Vos JA, Martin KH, Senft JR, Wenger SL, Gibson LF. RepSox slows decay of CD34C acute myeloid leukemia cells and decreases T cell immunoglobulin mucin-3 expression. Stem cells translational medicine 2014; 3:836-48; PMID:24855276; http://dx.doi.org/10.5966/sctm.2013-01932462
35. Jiang J, Jin MS, Kong F, Cao D, Ma HX, Jia Z, Wang YP, Suo J, Cao X. Decreased galectin-9 and increased Tim-3 expression are related to poor prognosis in gastric cancer. PloS one 2013; 8:e81799; PMID:24339967; http://dx.doi.org/10.1371/journal.pone.0081799
36. Zhuang X, Zhang X, Xia X, Zhang C, Liang X, Gao L, Zhang X, Ma C. Ectopic expression of TIM-3 in lung cancers: a potential independent prognostic factor for patients with NSCLC. Ameri can journal of clinical pathology 2012; 137:978-85; PMID:22586058; http://dx.doi.org/10.1309/AJCP9Q6OVLVSHTMY
37. Cao Y, Zhou X, Huang X, Li Q, Gao L, Jiang L, Huang M, Zhou J. Tim-3 expression in cervical cancer promotes tumor metastasis. PloS one 2013; 8:e53834; PMID:23335978; http://dx.doi.org/10.1371/journal.pone.0053834
38. Wu J, Liu C, Qian S, Hou H. The expression of Tim-3 in peripheral blood of ovarian cancer. DNA and cell biology 2013; 32:648-53; PMID:24007284; http://dx.doi.org/10.1089/dna.2013.2116
39. Piao YR, Piao LZ, Zhu LH, Jin ZH, Dong XZ. Prognostic value of T cell immunoglobulin mucin-3 in prostate cancer. Asian Pacific journal of cancer prevention: APJCP 2013; 14:3897-901; PMID:23886204; http://dx.doi.org/10.7314/APJCP.2013.14.6.3897
40. Li H, Wu K, Tao K, Chen L, Zheng Q, Lu X, Liu J, Shi L, Liu C, Wang G, et al. Tim-3/galectin-9 signaling pathway mediates T-cell dysfunction and predicts poor prognosis in patients with hepatitis B virus-associated hepatocellular carcinoma. Hepatology 2012; 56:1342-51; PMID:22505239; http://dx.doi.org/10.1002/hep.25777
41. Bai J, Li X, Tong D, Shi W, Song H, Li Q. T-cell immunoglobulinand mucin-domain-containing molecule 3 gene polymorphisms and prognosis of nonsmall-cell lung cancer. Tumour biology: the journal of the International Society for Oncodevelopmental Biology and Medicine 2013; 34:805-9; PMID:23359271; http://dx.doi.org/10.1007/s13277-012-0610-1
42. Tong D, Zhou Y, Chen W, Deng Y, Li L, Jia Z, Qi D. T cell immunoglobulinand mucin-domain-containing molecule 3 gene polymorphisms and susceptibility to pancreatic cancer. Molecular biology reports 2012; 39:9941-6; PMID:22733499; http://dx.doi.org/10.1007/s11033-012-1862-y
43. Cai C, Wang L, Wu Z, Li M, Chen W, Sun Y. T-cell immunoglobulinand mucin-domain-containing molecule 3 gene polymorphisms and renal cell carcinoma. DNA and cell biology 2012; 31:1285-9; PMID:22472081; http://dx.doi.org/10.1089/dna.2012.1625
44. Li Z, Li N, Zhu Q, Zhang G, Han Q, Zhang P, Xun M, Wang Y, Zeng X, Yang C, et al. Genetic variations of PD1 and TIM3 are differentially and interactively associated with the development of cirrhosis and HCC in patients with chronic HBV infection. Infection, genetics and evolution: journal of molecular epidemiology and evolutionary genetics in infectious diseases 2013; 14:240-6; PMID:23291409; http://dx.doi.org/10.1016/j.meegid.2012.12.008
45. Cao B, Zhu L, Zhu S, Li D, Zhang C, Xu C, Zhang S. Genetic variations and haplotypes in TIM-3 gene and the risk of gastric cancer. Cancer immunology, immunotherapy: CII 2010; 59:1851-7; PMID:20811886; http://dx.doi.org/10.1007/s00262-010-0910-5